Belgium: Galapagos increases share capital through rights issue

Galapagos, a fully integrated biotechnology company, has increased share capital through a subscription rights issue. The firm has issued 61,560 new ordinary shares for a total capital increase (including issuance premium) of €1,769,850 (Around US$1.9bn). Total share capital currently amounts to €356,444,938. Founded in 1999 as a joint venture between Crucell and Tibotec, Galapagos has R&D…